Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号：S2247 别名： NVP-BKM120 中文名称：布帕尼西

CAS No. 944396-07-0

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂，在无细胞试验中作用于p110α/β/δ/γ的IC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34，mTOR，DNAPK 的作用效果下降，而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2227.95	现货
5mg	RMB 1400.12	现货
10mg	RMB 2607.65	现货
50mg	RMB 7928.28	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献208篇：

Cancer Cell, 2021, S1535-6108(21)00284-1

PubMed: 34171264 ( click the link to review the publication )

Cell, 2020, 25;181(7):1596-1611.e27.

PubMed: 32559461 ( click the link to review the publication )

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):183-199

PubMed: 31978326 ( click the link to review the publication )

Nat Immunol, 2020, 21(4):442-454

PubMed: 32152508 ( click the link to review the publication )

Science, 2019, 364(6441)

PubMed: 31097636 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(1):91-107

PubMed: 29316436 ( click the link to review the publication )

Cell, 2017, 161(4):803-16

PubMed: 25913192 ( click the link to review the publication )

Cancer Discov, 2017, 7(9):1018-1029

PubMed: 28619981 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):232-45

PubMed: 24356096 ( click the link to review the publication )

Cancer Discov, 2013, 4(2):186-99

PubMed: 24302555 ( click the link to review the publication )

Cell, 2012, 27;149(3):656-70.

PubMed: 22541435 ( click the link to review the publication )

Nat Med, 2012, 18(6):892-901

PubMed: 22610277 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(21)00232-X

PubMed: 33909988 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1920

PubMed: 33772001 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3140

PubMed: 34035258 ( click the link to review the publication )

Theranostics, 2021, 11(8):3552-3564

PubMed: 33664847 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )
Cell Death Dis, 2021, 12(6):546

PubMed: 34039959 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):400

PubMed: 33854046 ( click the link to review the publication )

Cancer Cell Int, 2021, 21(1):24

PubMed: 33407478 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

Oncotarget, 2021, 12(7):674-685

PubMed: 33868588 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2500

PubMed: 32899250 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01074-2

PubMed: 32963347 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(11):3765-3783

PubMed: 33294266 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4488-4497

PubMed: 33415013 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16208

PubMed: 33004905 ( click the link to review the publication )

Front Neurosci, 2020, 2;14:223

PubMed: 32300287 ( click the link to review the publication )

Eur J Pharmacol, 2020, 870:172821

PubMed: 31770526 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Genes Cancer, 2020, 11(3-4):106-121

PubMed: 33488949 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):724

PubMed: 32758183 ( click the link to review the publication )

FASEB Bioadv, 2020, 2(2):126-144

PubMed: 32123862 ( click the link to review the publication )

Commun Biol, 2020, 3(1):593

PubMed: 33087841 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )
Mol Oncol, 2020, 10.1002/1878-0261.12673

PubMed: 32191822 ( click the link to review the publication )

Cancer, 2020, 10.1002/cncr.33071

PubMed: 32767682 ( click the link to review the publication )

Small GTPases, 2020, 10.1080/21541248

PubMed: 32043900 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(2):226-237

PubMed: 30692625 ( click the link to review the publication )

Nat Commun, 2019, 10(1):259

PubMed: 30651547 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1061-1076

PubMed: 30825612 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0556-z

PubMed: 31462739 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(8):2380-2394

PubMed: 31149050 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2317-2330

PubMed: 31461649 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0422-6

PubMed: 31570855 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E37

PubMed: 30609754 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Mol Ther Oncolytics, 2019, 13:58-66

PubMed: 31016228 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):834-844

PubMed: 30787173 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(18):7780-7795

PubMed: 31545294 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2774-2788

PubMed: 31911861 ( click the link to review the publication )

J Cell Physiol, 2019, 234(7):10907-10917

PubMed: 30536897 ( click the link to review the publication )
Front Oncol, 2019, 0.87569444444

PubMed: 31428587 ( click the link to review the publication )

Front Oncol, 2019, 9:1119

PubMed: 31750239 ( click the link to review the publication )

Eur J Immunol, 2019, doi: 101002/eji201948241

PubMed: 31621069 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Biochem J, 2019, 476(23):3583-3593

PubMed: 31738383 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Chem Biol Interact, 2019, 302:101-107

PubMed: 30703376 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211

PubMed: 30947576 ( click the link to review the publication )

Int J Hematol, 2019, 110(2):213-227

PubMed: 31129802 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

Oncol Lett, 2019, 18(6):6249-6260

PubMed: 31788102 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 05:31

PubMed: 31552290 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1357

PubMed: 29636477 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(5)

PubMed: 29650805 ( click the link to review the publication )

Cancer Res, 2018, 78(8):2000-2013

PubMed: 29437705 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

NPJ Genom Med, 2018, 3:15

PubMed: 29951225 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )
Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

Cell Rep, 2018, 24(2):463-478

PubMed: 29996106 ( click the link to review the publication )

Elife, 2018, 7e33718

PubMed: 30475204 ( click the link to review the publication )

Int J Cancer, 2018, 143(5):1188-1201

PubMed: 29582409 ( click the link to review the publication )

Int J Cancer, 2018, 142(9):1926-1937

PubMed: 29210065 ( click the link to review the publication )

Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 439:56-65

PubMed: 30243708 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29535262 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2049-2059

PubMed: 29970482 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10784

PubMed: 30018387 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3223-3234

PubMed: 30272286 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):3321-3328

PubMed: 29435074 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Oncotarget, 2018, 9(56):30869-30882

PubMed: 30112114 ( click the link to review the publication )

J Exp Med, 2018, 215(1):159-175

PubMed: 29141866 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8:15021

PubMed: 28443643 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Dev Cell, 2017, 43(6):673-688

PubMed: 29103956 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(41):E8628-E8636

PubMed: 28973876 ( click the link to review the publication )

Cancer Res, 2017, 77(16):4448-4459

PubMed: 28652248 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163

PubMed: 28119489 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Cell Proteomics, 2017, 16(10):1864-1888

PubMed: 28794006 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

SLAS Discov, 2017, 22(8):974-984

PubMed: 28644734 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7878-7890

PubMed: 28002802 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52474-52487

PubMed: 28881745 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(13):21806-21817

PubMed: 28423521 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29137323 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6608-6622

PubMed: 28036259 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1324-1335

PubMed: 27870828 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(3):644-56.

PubMed: 26224873 ( click the link to review the publication )

PLoS Biol, 2016, 14(11):e1002581

PubMed: 27880766 ( click the link to review the publication )

Cancer Res, 2016, 76(24):7168-7180

PubMed: 27913436 ( click the link to review the publication )
Cell Rep, 2016,

PubMed: 27292631 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):113

PubMed: 27765055 ( click the link to review the publication )

Cancer Discov, 2016, 6(10):1134-1147

PubMed: 27604488 ( click the link to review the publication )

J Transl Med, 2016, 14:56

PubMed: 26912358 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:308-317

PubMed: 27599915 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0147682

PubMed: 26821351 ( click the link to review the publication )

PLoS One, 2016, 10.1371/journal

PubMed: 27055253 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45414-45428

PubMed: 27323778 ( click the link to review the publication )

Oncotarget, 2016, 7(41):67277-67287

PubMed: 27572309 ( click the link to review the publication )

Nature, 2016, 529(7586):413-417

PubMed: 26735014 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Sci Rep, 2016, 6:20189

PubMed: 26846842 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI78018

PubMed: 25798617 ( click the link to review the publication )

J Clin Invest, 2015, 125(12):4559-71

PubMed: 26529251 ( click the link to review the publication )

Genes Dev, 2015, 29(16):1677-82

PubMed: 26272820 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(28):8638-43

PubMed: 26124089 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2851-62

PubMed: 25977330 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.173

PubMed: 25982275 ( click the link to review the publication )

Glia, 2015, 63(10):1850-9

PubMed: 25944104 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1194-209

PubMed: 26293922 ( click the link to review the publication )

Gynecol Oncol, 2015, 138(1):165-73

PubMed: 25933683 ( click the link to review the publication )

Biomed Pharmacother, 2015, 75:40-50

PubMed: 26463630 ( click the link to review the publication )
Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Cell Signal, 2015, 27(12):2389-400

PubMed: 26363466 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 60C:34-42

PubMed: 25578563 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):675-85

PubMed: 26256696 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Immunol Res, 2015, 10.1007/s12026-015-8648-y

PubMed: 25869396 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10399-414

PubMed: 25871383 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

J Clin Invest, 2014, 124(12):5490-502

PubMed: 25401474 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

J Exp Med, 2014, 211(13):2497-2505

PubMed: 25488980 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Rep, 2014, 8(5):1265-70

PubMed: 25176649 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

PLoS Pathog, 2014, 10(6):e1004196

PubMed: 24945378 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(1):R9

PubMed: 24451154 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )
Mol Cancer Res, 2014, 12(10):1520-31

PubMed: 25103499 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108780

PubMed: 25360799 ( click the link to review the publication )

PLoS One, 2014, 9(7):e101969

PubMed: 25003333 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(21):5940-51

PubMed: 23918606 ( click the link to review the publication )

Cancer Res, 2013, 73(17):5459-72

PubMed: 23796563 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.509

PubMed: 24292683 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R55

PubMed: 23844554 ( click the link to review the publication )

Cell Commun Signal, 2013, 11(1):3

PubMed: 23311350 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

BMC Cancer, 2013, 13:465

PubMed: 24103747 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

University Gattingen, 2013, Elisabeth Hand

PubMed: ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

BKM120是可用于口服的生物有效的PI3K抑制剂。

靶点

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	Vps34 ^[1] (Cell-free assay)	点击更多
52 nM	116 nM	166 nM	262 nM	2.4 μM	点击更多

体外研究

BKM120作用于解除PI3K调节的细胞系，包括A2780, U87MG, MCF7和DU145时，具有抗增殖活性，GI50为0.1-0.7 nM。^[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡，导致G1期细胞增多，S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡，且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。^[2]BKM120作用于人类胃癌细胞系，降低mTOR下游信号，具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系，可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞，诱导凋亡，具有协同效应，但是作用于KRAS野生型细胞没有这种效果。^[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
glioma cell lines	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV;DdFlWPzKq		MlLqTWM2OD1zLUNOwG0>	NXHYeYJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwOlUxQDBpPkKyNFY2ODhyPD;hQi=>
U87	M3fmcmFxd3C2b4Ppd{BCe3OjeR?=	M3LNPVLPxE1?	MojVO\|Jp		MkHTbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCjbnSgZ4xm[X[nZDDQRXJRKGGwZDDjZZNx[XOnLUO=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB4NUC4NEc,OjJyNkWwPFA9N2F-
SNU-601	NYTPXJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWGxe3ZQPzKq	NYHjVFhsTE2VTx?=	MnvNTWM2OD1yLkixOuKyOC5yNkROwG0>	NH3wPWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-1	M2DuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX23Nog>	MmXwSG1UVw>?	MXTJR\|UxRTFwMEiyxtExNjB{ON88US=>	NUHxSZJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-668	NETQWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEm2Opg4Omh?	NY\4WGFzTE2VTx?=	NYfCS4xEUUN3ME2xMlU4QcLzMD6wO\|TPxE1?	NH64UXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
AGS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUDPeYlIPzKq	NEnlR2hFVVOR	M3XGXmlEPTB;MT63NVTDuTBwMUG3{txO	NVjmNIJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
SNU-216	MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLWO\|Jp	MYXEUXNQ	MlrPTWM2OD1{Lk[5NuKyOC5yOENOwG0>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF3OUixOEc,OjJzNUm4NVQ9N2F-
SNU-5	NHHDWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlPqO\|Jp	NIH1WpdFVVOR	NFjqPHpKSzVyPUGuN\|UyyrFyLkC5Ne69VQ>?	NFjyeVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-638	NH3qN49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mlu3O\|Jp	NHfRflVFVVOR	NVXUXot2UUN3ME2yMlI5OsLzMD6wOVPPxE1?	M4fNeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW5PFE1Lz5{MkG1PVgyPDxxYU6=
SNU-16	M4rCNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoDsO\|Jp	NFmwT5dFVVOR	NGrpTJhKSzVyPUGuOVc{yrFyLkCwNe69VQ>?	NHjoTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1PVgyPCd-MkKxOVk5OTR:L3G+
SNU-484	MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkHRO\|Jp	M1v3V2ROW09?	MXrJR\|UxRTFwN{K4xtExNjB2Nd88US=>	MmHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-620	NWPLeWF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWLXVIJzPzKq	NF;SbFRFVVOR	Mlu1TWM2OD1{LkmzPeKyOC5yMEJOwG0>	MlTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUm4NVQoRjJ{MUW5PFE1RC:jPh?=
SNU-719	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NE\wUFI4Omh?	MUTEUXNQ	NHewNWNKSzVyPUOuNFM4yrFyLkCzNu69VQ>?	NVHhVZhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVk5OTRpPkKyNVU6QDF2PD;hQi=>
MM cell lines	MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfQWG8yOM7:TR?=	M1vFSFI1cA>?	NU[zO2I4TE2VTx?=	M4LXZmlEPTBidnHybYV{KGGvb37nJIRq\m[ncnXueEBk\WyuIHzpcoV{KGmwIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y5k\Q>?	M2\lZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3OFg2Lz5{MkKwO\|Q5PTxxYU6=
ARP-1	NGL5ZpRCeG:ydH;zbZMhSXO\|YYm=	M{m0e\|Ex\|ryP	MljTNlRp	NWLkbo5HTE2VTx?=	MlWxbY5lfWOnczDNUUBk\WyuIHHwc5B1d3OrczD0bJJwfWeqIHPhd5Bie2ViYXP0bZZifGmxbh?=	NYr5TGd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc1QDVpPkKyNlA4PDh3PD;hQi=>
colon cancer cell lines	M37qXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z2clAuOTEQvF2=	NWHLWGV2PzKq	MUPEUXNQ	NIjyfG1KSzVyPUJOwG0>	NVfRXWVuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1OFM5PTdpPkKyOVQ{QDV5PD;hQi=>
gastric cancer cell lines	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSwMVEx\|ryP	MnPUO\|Jp	M1izRWROW09?	MlXkTWM2OD1{LUZOwG0>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2M{i1O{c,OjJ3NEO4OVc9N2F-
HCT-116/HT-29/MKN-45	NVfqTodvSXCxcITvd4l{KEG\|c3H5	M4XIeVLPxE1?	MU[0PIg>		Mn;3d4hq\nRiaX6gS\|IheGijc3W=	NEHqOoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0N\|g2Pyd-MkK1OFM5PTd:L3G+
HT-29 and HCT-116	NHrGTm5E[XOyYYPlJIF{e2G7	M4S3[VXPxE1?	MYeyOIg>		M1Lab4lv\HWlZYOgZ4F{eGG\|ZTDhZ5Rqfmm2eR?=	M2DHSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSzPFU4Lz5{MkW0N\|g2PzxxYU6=
PIK3CA-mutant MCF7	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFv1Vo1IUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?=	MVi3Nog>		MoLvS2k2OD1zNkFCtVkydk4xvJzMSFUxRTl6MNMxNlc{dk1?	NXrPbGsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2OVM6PjdpPkKyOlU{QTZ5PD;hQi=>
PIK3CA-mutant MCF7	NVrse2IzU2mwYYPlJGF{e2G7	MWnJR\|UxRTFzNNMxN45O	M2LzN\|czcA>?		MUfJR\|UxRTFzNNMxN45OKGmwIILl[JVkcW6pIFHreEBxcG:\|cHjvdplt[XSrb36gcIV3\Wy\|	MmK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
MCF7-myr-Akt	M3i2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrDR\|FIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?=	Mk\zO\|Jp		NGT4OXdIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?=	MkDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4NUO5OlcoRjJ{NkWzPVY4RC:jPh?=
Y1 cell line	NH:1NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFe1TnkxNjIQvF2vNe69VQ>?	Mli2NlRp	Mo[3SG1UVw>?	M4j1bolvcGmkaYTzJFYx97zHIHPlcIwhfmmjYnnsbZR6KGmwIF35Z{1U[3S{LYTyZY5{\mWldHXkJINmdGy\|	NWHlW41ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK2PVI6ODRpPkKyOlkzQTB2PD;hQi=>
human NSCLC	NIPtOYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInKNVAxNjVvMt88US=>	M4PBTFczcA>?		NUG3RolwUUN3ME2x{txO	Mm\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5OEGzPVMoRjJ{N{ixN\|k{RC:jPh?=
human NSCLC	NXLGSpZSU2mwYYPlJGF{e2G7	NW\MdWlJOc7:TR?=	NVXtbZB[OjSq		NWjYO\|lncW6qaXLpeJMhfGinIFHreE9uXE:UIIPp[45idGmwZzDwZZRpf2G7IHH0JFNpKGGodHXyJJRz\WG2bXXueC=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd6MUO5N{c,OjJ5OEGzPVM9N2F-
JVM2	NXSxXVlGS3m2b4TvfIlkcXS7IHHzd4F6	NHTYPIwxNjJvMkFOwG0>	M3e5S\|czcA>?	NV7Oem95TE2VTx?=	MYLJR\|UxRTBwOd88US=>	M2XrblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
EHEB	MUDDfZRwfG:6aXPpeJkh[XO\|YYm=	NFGzTJIxNjJvMkFOwG0>	Mo[0O\|Jp	NVrtPHJWTE2VTx?=	MV\JR\|UxRTBwN988US=>	M{K2bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
MEC2	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=	M4HVNFAvOi1{MN88US=>	MkT1O\|Jp	M4f0NGROW09?	MVjJR\|UxRTBwN988US=>	NV3WcItHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	NXvYSoRQSXCxcITvd4l{KEG\|c3H5	M3nsZWlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV?	M2fsdlI1cA>?	MUjEUXNQ	NV7YNnhwUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>?	NVXOb4JbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|g3OzlpPkKzNlM5PjN7PD;hQi=>
primary B-CLL lymphocytes	NXvtUnZFU2mwYYPlJGF{e2G7	M2m0fGlEPTBiZn;yJIVi[2hicILpcYFzgSClZXzsJIxqdmV?	MYqyOIg>		MV\pcohq[mm2czDwO\|BUPktiJjC0SU1DWDFiZYjwdoV{e2mxbh?=	M3;Xc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkO4OlM6Lz5{M{KzPFY{QTxxYU6=
SK-HEP1	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVWxMVIx\|ryP	MkDGO\|Jp	NWPzTYhiTE2VTx?=	M4W5NmlEPTExvKyx{txO	NV7x[3BORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0O\|kyOzZpPkKzOFc6OTN4PD;hQi=>
786-0	NYXwc\|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnHZpoyNTJyzszN	NUPmTo83PzKq	M17x[2ROW09?	NHnrU45KSzVy78{cNe69VQ>?	NILGZoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S3PVE{Pid-MkO0O\|kyOzZ:L3G+
human HCC cell lines	NXfCWmlSS2WubDD2bYFjcWyrdImgZZN{[Xl?	MXKwMlAxPS1zzszN	Mmm2OFhp		M1TR[GlEPTB;Md88US=>	MoXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OEm5PVkoRjJ\|NEi5PVk6RC:jPh?=
Huh7	MkPrT4lv[XOnIFHzd4F6	M4jmV\|HPxE1?	M2PUOFQ5cA>?		M3;IeZNq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=>	M2m5WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEi5PVk6Lz5{M{S4PVk6QTxxYU6=
human NSCLC cell lines	MmfWRZBweHSxc3nzJGF{e2G7	MVGwMlEzPS12zszN	NYLRfnRiOjSq	MXrEUXNQ	NVXzUGZ5UUN3MIOgdoFv\2W\|IH\yc40hOC52LUNOwG0>	M{S5SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[yOFczLz5{M{W2NlQ4OjxxYU6=
Primary CLL cells	MkfSRZBweHSxc3nzJGF{e2G7	M2DMXFEuOTEQvF2=	M1nnTVQ5cA>?		NIrlT3VqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCFTFygZ4VtdHNiaX7k[ZBmdmSnboSgc4YheHKxZ37vd5Rq[yCvYYLr[ZJ{	MkLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC4NFcoRjJ\|OEWwPFA4RC:jPh?=
Primary CLL cells	MWLLbY5ie2ViQYPzZZk>	NI\5R5Qz\|ryP	MYGzNI1qdg>?		M2\ocYRm[3KnYYPl[EBRUTONIHHjeIl3cXS7	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh3MEiwO{c,OjN6NUC4NFc9N2F-
Primary CLL cells	MX\DfZRwfG:6aXOgRZN{[Xl?	MX6y{txO	M2PxeFI1cA>?		M1LpXolv\HWlZYOgZ4VtdCCleYTveI95cWOrdIm=	NXfUT4ZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OVA5ODdpPkKzPFUxQDB5PD;hQi=>
LC-1/SQSF	NEnPUVdHfW6ldHnvckBCe3OjeR?=	MWmz{txO	MkjFNlRp	NI\2[JpFVVOR	M3fOZYRm[3KnYYPlJG5TTjJicILveIVqdiCuZY\lcC=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6MEC5N{c,OjN7OECwPVM9N2F-
BCR-ABL	NYP5SGhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjENE4zPS1zMN88US=>	MV[0[C=>		MX7zbYdvcW[rY3HueIx6KGmwaHnibZQh[2WubDDwdo9tcW[ncnH0bY9v	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ2NE[xNkc,OjR{NES2NVI9N2F-
T-ALL	NEj4PHhCeG:ydH;zbZMhSXO\|YYm=	NIn4UHZj\XS5ZXXuJFEvPCCjbnSgOU4{KG2PIHH0JFI1cCCjbnSgNE46KGGwZDC1MlUhdU1iYYSgOFhpKGmwIHTp[oZmemWwdDDj[YxtKGyrbnW=	Ml3JNlQhd3JiNEjo	MnS2SG1UVw>?	Ml;wZYZn\WO2czD0bIUhWEl\|SzDwZZRpf2G7IHnuJHQuSUyOIHPlcIwhdGmwZYO=	MkDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|MUC3N\|YoRjJ2M{GwO\|M3RC:jPh?=
H1975	NH7nbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TZO\|AvOy17LkdOwG0>	MkjUO\|Jp	NIewT5RFVVOR	NFHPToJKSzVyPUGuN\|g2\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|N{i0Okc,OjR\|M{e4OFY9N2F-
H1975	NXfXdXpkSXCxcITvd4l{KEG\|c3H5	NXPWZW0zOs7:TR?=	NYfjSIN4OjSq	M3zZRmROW09?	NFK5[FBqdmO{ZXHz[ZMh[XCxcITvd4l{KHKjdHWgd4lodmmoaXPhcpRtgQ>?	MofsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{e4OFYoRjJ2M{O3PFQ3RC:jPh?=
BON	NXf1bXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG4NU02\|ryP	Mn\IO\|Jp		NVy2[WJE\GWlcnXhd4V{KGOnbHygdJJwdGmoZYLheIlwdg>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR2M{WyN{c,OjR2NEO1NlM9N2F-
BON	NX7FU2FqSXCxcITvd4l{KEG\|c3H5	MYKxMVXPxE1?	M1TWVFI1cA>?		M{CzNIlv[3KnYYPld{BieG:ydH;zbZM>	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2NEO1NlMoRjJ2NESzOVI{RC:jPh?=
GBM	MmP0RZBweHSxc3nzJGF{e2G7	NXTYZW9WOs7:TR?=	NILSPWw1QGh?	NEnwU\|FFVVOR	NYn3eXFHcW6mdXPl[EBpcWeqZYKgcIV3\Wy\|IH;mJIFxd3C2b4Ppd{wh[W6mIHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gQ>?	NV7xSW12RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFA1QTJpPkK0OVAxPDl{PD;hQi=>
FaDu	MoXqSpVv[3Srb36gRZN{[Xl?	MkDvOUDPxE1?	Mn3INlQhcA>?	M1PCUGROW09?	M2LOOXJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUG0O{c,OjR4M{GxOFc9N2F-
EMT6	Mk\KSpVv[3Srb36gRZN{[Xl?	NEXndnA2KM7:TR?=	NUTYfpFuOjRiaB?=	MnroSG1UVw>?	Ml;xVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36=	M2HPdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxNVQ4Lz5{NE[zNVE1PzxxYU6=
HCT116	NF7sR3hHfW6ldHnvckBCe3OjeR?=	NHLFOW82KM7:TR?=	M1LKSVI1KGh?	Mo\GSG1UVw>?	MWfS[YR2[2W\|IH;4fYdmdiClb37zeY1xfGmxbh?=	NYrzSoFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2N\|EyPDdpPkK0OlMyOTR5PD;hQi=>
U87	M{j4RmZ2dmO2aX;uJGF{e2G7	MV[1JO69VQ>?	MUCyOEBp	M1vKVmROW09?	M1r5cnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u	MnuyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GxOFcoRjJ2NkOxNVQ4RC:jPh?=
Saos-2	MlPvSpVv[3Srb36gRZN{[Xl?	M4\hZ\|UxKM7:TR?=	M4[yblQ5KGh?		NWqxTZN5UW6qaXLpeJMh[2WubDDpcpZie2mxbh?=	MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63	M4ThOmZ2dmO2aX;uJGF{e2G7	MlKzOVAh\|ryP	NF\IcmI1QCCq		NFvS[HVKdmirYnn0d{Bk\WyuIHnueoF{cW:w	MlP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
SJSA-1	NWLVdndjTnWwY4Tpc44hSXO\|YYm=	NGLWbHo2OCEQvF2=	NETRe2E1QCCq		MV3Jcohq[mm2czDj[YxtKGmwdnHzbY9v	NFzmSnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
Saos-2	NVrLNFdpTnWwY4Tpc44hSXO\|YYm=	MlLVOVAh\|ryP	M2H1dFQ5KGh?		NF3SNVVKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v	NVLDeXBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
MG-63	MWXGeY5kfGmxbjDBd5NigQ>?	NWLoSYZmPTBizszN	MX60PEBp		MoK5TY5pcWKrdIOgcYF1emm6IH3leIFtdG:ycn;0[Ylv[XOnLUKg[ZhxemW\|c3nvci=>	NHXBdlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
SJSA-1	Mk[5SpVv[3Srb36gRZN{[Xl?	NF7YTZE2OCEQvF2=	Mn\nOFghcA>?		NHHTNZFKdmirYnn0d{Bu[XS{aYigcYV1[Wyub4Dyc5RmcW6jc3WtNkBmgHC{ZYPzbY9v	NUDxOmxjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Nlc3PjBpPkK0O\|I4PjZyPD;hQi=>
Saos-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUH2ZpB1PTBizszN	NIj5dms1QCCq		M{PXVWlvcGmkaYTzJINmdGxidnnhZoltcXS7	Moj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Mke2OlAoRjJ2N{K3OlYxRC:jPh?=
MG-63	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYm1NEDPxE1?	NIPGeGU1QCCq		MXLJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	M2TDflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{K3OlYxLz5{NEeyO\|Y3ODxxYU6=
SJSA-1	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\vOVAh\|ryP	M1XFb\|Q5KGh?		MVXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?	NEKxcGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEeyO\|Y3OCd-MkS3Nlc3PjB:L3G+
LN18	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKyNEDPxE1?	MmXTO\|IhcA>?	MWfEUXNQ	MXHJR\|UxRDVizszN	NI\oT4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe0NVA4PCd-MkS3OFExPzR:L3G+
LN229	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fXeFIxKM7:TR?=	MlLoO\|IhcA>?	NVfE[ZltTE2VTx?=	MlHzTWM2ODx3IN88US=>	NYrIeVI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LNZ308	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\VNlAh\|ryP	MkKwO\|IhcA>?	MV;EUXNQ	MomyTWM2ODx3IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
T98G	M{LSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DRZ\|IxKM7:TR?=	M2nH[FczKGh?	NITwV4hFVVOR	M3nN[WlEPTB:NTFOwG0>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd2MUC3OEc,OjR5NEGwO\|Q9N2F-
U87	M13IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXP3PZdROjBizszN	NEXsNYM4OiCq	NVLzSVR[TE2VTx?=	Mof3TWM2ODx3IN88US=>	MlXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
LN18	MX7GeY5kfGmxbjDBd5NigQ>?	NEL3WIo2KM7:TR?=	NV21UWhOOjRiaB?=	M2fvVGROW09?	M1flN2lvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?	NYK1V3djRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3OFExPzRpPkK0O\|QyODd2PD;hQi=>
LNZ308	NWXaOlkyTnWwY4Tpc44hSXO\|YYm=	NFHm[nk2KM7:TR?=	NHnNXlIzPCCq	NInLUI5FVVOR	MlrvTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?	MkjwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NEGwO\|QoRjJ2N{SxNFc1RC:jPh?=
MDA-MB-175	NE\uTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxJO69VQ>?	M3LIdVUh\A>?	MnLhSG1UVw>?	NI\Db2hKSzVyPEGg{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
MDA-MB-134	NVLUZWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvDNUDPxE1?	NVHDPJVUPSCm	NGC1U4JFVVOR	M1LHSmlEPTB:MTFOwG0>	Ml63QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1500	NY\JU\|dST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjPTncyKM7:TR?=	M37iclUh\A>?	M4nobWROW09?	MX\JR\|UxRDFizszN	NETu[nc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
EFM-19	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37RTFEh\|ryP	MnjaOUBl	NGnLW\|lFVVOR	Mlq3TWM2ODxzIN88US=>	M{DXU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
ZR-75-30	NYDDNnVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1ryRlEh\|ryP	M1mwclUh\A>?	NEnmcHZFVVOR	NGTDNllKSzVyPEGg{txO	Mki5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-361	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWGxJO69VQ>?	M2LBNVUh\A>?	MXrEUXNQ	NXmwWJJiUUN3MEyxJO69VQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
T-47D	NWrwXVMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DIOlEh\|ryP	NV3oblNsPSCm	NV64NnpYTE2VTx?=	MlPVTWM2ODxzIN88US=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
SK-BR-3	NYWx[5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF30PZgyKM7:TR?=	NEPKc3I2KGR?	MnG5SG1UVw>?	MY\JR\|UxRDFizszN	NWLYc4h{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
UACC-732	Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVOxJO69VQ>?	NE\ZTpM2KGR?	NWTj[3pjTE2VTx?=	NF\NW\|dKSzVyPEGg{txO	NX3qUmx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
BT-474	M1fwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:zNUDPxE1?	M{K3blUh\A>?	MWrEUXNQ	M3fpcWlEPTB:MTFOwG0>	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC202	M4THTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXieJlXOSEQvF2=	NVju[3ljPSCm	NV3IVZdDTE2VTx?=	MVHJR\|UxRDFizszN	MkDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MCF7	M4XIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWOxJO69VQ>?	NG\CU5M2KGR?	M2fKXWROW09?	MlLFTWM2ODxzIN88US=>	Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-415	NUfnW5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xJO69VQ>?	Mlz6OUBl	M1H3RmROW09?	MoDHTWM2ODxzIN88US=>	NVzKcpQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
MDA-MB-453	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLwNUDPxE1?	NFfSRXU2KGR?	NUnzO4J4TE2VTx?=	NFL3VZhKSzVyPEGg{txO	NVrLR\|g5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
ZR-75-1	M2\4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULGTmpFOSEQvF2=	M1rBXFUh\A>?	MVPEUXNQ	MnfiTWM2ODxzIN88US=>	NXrwcmo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC38	NFW2cFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzVflQyKM7:TR?=	NU\4dG96PSCm	MonLSG1UVw>?	M1rDXWlEPTB:MTFOwG0>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1419	NFLidXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\2NUDPxE1?	MVq1JIQ>	NIXnU\|FFVVOR	NVjMVIx4UUN3MEyxJO69VQ>?	Mo[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
UACC-812	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnRNUDPxE1?	MYq1JIQ>	MlrlSG1UVw>?	NXi2XXFMUUN3MEyxJO69VQ>?	NWXxXnN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1187	NG\6WFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4W2VFEh\|ryP	NGfFb3k2KGR?	MV3EUXNQ	NVPCWItJUUN3MEyxJO69VQ>?	NEnCSXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
KPL-1	NWXrfW1ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nYelEh\|ryP	NHPDd442KGR?	Mm\FSG1UVw>?	NEG4U29KSzVyPEGg{txO	NEi4O2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
SUM-225	NGD4OXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TLe\|Eh\|ryP	NGrQRWU2KGR?	MWXEUXNQ	Mmm5TWM2ODxzIN88US=>	NFnoN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3PVc6Pid-MkS4O\|k4QTZ:L3G+
EFM-192A	MkTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfKblgyKM7:TR?=	NGjiNWc2KGR?	NV24VZdTTE2VTx?=	MUHJR\|UxRDFizszN	M{jJS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
JIMT-1	M2\6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWixJO69VQ>?	M1P2TFUh\A>?	MX\EUXNQ	NELQRZdKSzVyPEGg{txO	Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC1143	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHvNUDPxE1?	M{WwbFUh\A>?	NHXpOXFFVVOR	M{fNRmlEPTB:MTFOwG0>	MoX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
HCC2218	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILBRY4yKM7:TR?=	MYO1JIQ>	NFXrN3BFVVOR	NXXEOol6UUN3MEyxJO69VQ>?	MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-468	MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHW1cpgyKM7:TR?=	M{G3RlUh\A>?	NITpVopFVVOR	MV\JR\|UxRDFizszN	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
BT-20	NYL6eGtMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHzNUDPxE1?	MknzOUBl	NWH2NI11TE2VTx?=	MkXkTWM2ODxzIN88US=>	MoqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MDA-MB-435	NYTUU2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2xJO69VQ>?	M3zRT\|Uh\A>?	M4DQcWROW09?	NV\2fmVIUUN3MEyxJO69VQ>?	MkLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
BT-549	Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPCb2wyKM7:TR?=	MlTOOUBl	Mk\vSG1UVw>?	NWi0N5BWUUN3MEyxJO69VQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5OUe5Okc,OjR6N{m3PVY9N2F-
HCC1806	MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq1R3RZOSEQvF2=	NEHLbJM2KGR?	MUXEUXNQ	M4f6[2lEPTB:MTFOwG0>	NXH3fJhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|k4QTZpPkK0PFc6Pzl4PD;hQi=>
HCC1937	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfwNUDPxE1?	M1qwblUh\A>?	MlyzSG1UVw>?	MX3JR\|UxRDFizszN	M2\wb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe5O\|k3Lz5{NEi3PVc6PjxxYU6=
Hs578T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq2VJhPOSEQvF2=	MWW1JIQ>	NWrVXIhlTE2VTx?=	MV3JR\|UxRDFizszN	MlfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{m3PVYoRjJ2OEe5O\|k3RC:jPh?=
MCF7	Mn;TR5l1d3SxeHnjJGF{e2G7		NGi1N\|c4OiCq	M1HpSGROW09?	MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKEV3NEXLJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMECxOVgh\|ryP	MlHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
DU145	NGHE[WNEgXSxdH;4bYMhSXO\|YYm=		MnzIO\|IhcA>?	M4CwOmROW09?	NXu2dnR4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN	Mo\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	M2fydGN6fG:2b4jpZ{BCe3OjeR?=		MWG3NkBp	MVHEUXNQ	NF;BXGZEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEK2Okc,OjR7MECyOlY9N2F-
U87MG	MULDfZRwfG:6aXOgRZN{[Xl?		NXi0NodrPzJiaB?=	M2nQfmROW09?	NFe4RWNEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3QThizszN	NVG0cYpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
A2780	MV;GeY5kfGmxbjDBd5NigQ>?		M1nafFEhcA>?	MnzySG1UVw>?	MXzJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>?	M{HCXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwNlY3Lz5{NEmwNFI3PjxxYU6=
DU145	M1nTNmZ2dmO2aX;uJGF{e2G7		M1v4XVEhcA>?	M2GzcGROW09?	Mn7FTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O\|MheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGijcnLvdolv\yCOS1KxJI12fGG2aX;uJJdqfGhiRVO1NEBw\iByLkC3N{DPxE1?	MoL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
A2780	M1rEb2Z2dmO2aX;uJGF{e2G7		NH;kZ\|IyKGh?	MX3EUXNQ	MXfJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:\|cHjvdplt[XSrb36gbY4hWFSHTj3k[YZq[2mnboSgbJVu[W5iQUK3PFAh[2WubIOge4l1cCCHQ{WwJI9nKDBwMEe0JO69VQ>?	NXrmSWdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFAzPjZpPkK0PVAxOjZ4PD;hQi=>
MCF7	MnrGSpVv[3Srb36gRZN{[Xl?		M2S3WlEhcA>?	MX7EUXNQ	M1rPUWlvcGmkaYTpc44hd2ZiUFmzT4FteGijIFW1OFVMKG23dHHueE1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckB4cXSqIFXDOVAhd2ZiMD6xJO69VQ>?	MmPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
U87MG	NF3nXWRHfW6ldHnvckBCe3OjeR?=		NHm2VWkyKGh?	MlzVSG1UVw>?	NGjMcpRKdmirYnn0bY9vKG:oIGDJN2sudWWmaXH0[YQhSUuWIGPldlQ4OyCyaH;zdIhwenmuYYTpc44hcW5iUGTFUk1l\W[rY3nlcpQhcHWvYX6gWVg4VUdiY3XscJMhf2m2aDDFR\|UxKG:oIECuNVMh\|ryP	NFe0NJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI3Pid-MkS5NFAzPjZ:L3G+
A2780	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M33vT\|czKGh?	M13DNmROW09?	NY\ScZVpTUN3ME2wMlUzKM7:TR?=	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MECyOlYoRjJ2OUCwNlY3RC:jPh?=
Huh7	NInZVoVHfW6ldHnvckBCe3OjeR?=	NHm4OmcyKM7:TR?=	NFj4d2EyKGh?	MW\EUXNQ	Mn\KTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDT[ZI1PzR?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByNESwN{c,OjVyMES0NFM9N2F-
BNL	MonrSpVv[3Srb36gRZN{[Xl?	NEXBZmcyKM7:TR?=	NFnDcGgyKGh?	NWq1NZV[TE2VTx?=	NHzzUpFKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhWzZ?	M4\pR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC0OFA{Lz5{NUCwOFQxOzxxYU6=
BON-1	NVnWUYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;zOVAxKG6P	NFzwfHUyOCCm	MUfEUXNQ	MYPJcohq[mm2czDj[YxtKGe{b4f0bC=>	NEHsXlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyOlI6Oid-MkWwNlYzQTJ:L3G+
BON-1	MojRSpVv[3Srb36gRZN{[Xl?	MoTKOVAxKG6P	MmqwOEBp	M4\1bGROW09?	NETSfFFKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMk[yPVIoRjJ3MEK2NlkzRC:jPh?=
QGP-1	MnvCSpVv[3Srb36gRZN{[Xl?	M3jpfFUxOCCwTR?=	MXy0JIg>	MkCxSG1UVw>?	NFzRdlBKdmirYnn0d{BxcG:\|cHjvdplt[XSrb36gc4YhSUuWIHH0JHRpejNyODDhcoQhW2W{NEez	NXzzNZJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlYzQTJpPkK1NFI3Ojl{PD;hQi=>
HCT-15	NV\QNY9RSXCxdH;zbZMhSXO\|YYm=	MXKxNEDPxE1?	M{jxcFQ5KGh?	MUfEUXNQ	NEX4dnpKdmS3Y3XzJIFxd3C2b4Ppd{BqdiCKQ2StNVUh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	M3\tc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
HCT-116	NV\tSGw3SXCxdH;zbZMhSXO\|YYm=	NXeyVlEzOTBizszN	M4G2OlQ5KGh?	NGDsV21FVVOR	NVvyO4lQUW6mdXPld{BieG:ydH;zbZMhcW5iSFPUMVEyPiClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S\|cH;0JI12fGG2aX;u	Mln5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
NCI-H460	MWfBdI91d3OrczDBd5NigQ>?	MnSxNVAh\|ryP	NYe2WHVCPDhiaB?=	M4frPWROW09?	MVXJcoR2[2W\|IHHwc5B1d3OrczDpckBPS0lvSES2NEBk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	MoqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
SKOV-3	M{nJRWFxd3Sxc3nzJGF{e2G7	M4n4SFExKM7:TR?=	Ml;2OFghcA>?	MXHEUXNQ	M{Hmemlv\HWlZYOgZZBweHSxc3nzJIlvKFONT2[tN{Bk\WyuczDoZZJjd3W{aX7nJHBKUzOFQTDoc5R{eG:2IH31eIF1cW:w	Mn3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
BSY-1	M1vXZmFxd3Sxc3nzJGF{e2G7	NFz0R3oyOCEQvF2=	MoPkOFghcA>?	M3\EVGROW09?	MV;JcoR2[2W\|IHHwc5B1d3OrczDpckBDW1lvMTDj[YxteyCqYYLic5VzcW6pIGDJT\|NESSCqb4TzdI91KG23dHH0bY9v	Mn;iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNUKyOFUoRjJ3MUWyNlQ2RC:jPh?=
MKN-1	NVLFcJh2SXCxdH;zbZMhSXO\|YYm=	NWPMXJRVOTBizszN	NEezeWc1QCCq	MVTEUXNQ	NVjDRYZ4UW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt\|Q1GgbI91e3CxdDDteZRifGmxbh?=	M{HFSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
NCI-H522	M1zFemFxd3Sxc3nzJGF{e2G7	NVL1Xod3OTBizszN	M3u4clQ5KGh?	NEKxSnpFVVOR	MnK4TY5lfWOnczDhdI9xfG:\|aYO=	M1\wW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
OVCAR-3	MlHhRZBwfG:\|aYOgRZN{[Xl?	M2XwNVExKM7:TR?=	NYrPPJM2PDhiaB?=	M4\LfGROW09?	NVq0d2xVUW6mdXPld{BieG:ydH;zbZM>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
HBC-5	MYXBdI91d3OrczDBd5NigQ>?	NGn1VIYyOCEQvF2=	NFHiNG41QCCq	NVX3fGhiTE2VTx?=	NUHPfI5OUW6mdXPld{BieG:ydH;zbZM>	NVP5bXZ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxOVIzPDVpPkK1NVUzOjR3PD;hQi=>
RXF-631L	NYXDOHZiSXCxdH;zbZMhSXO\|YYm=	M1z6TFExKM7:TR?=	MoXCOFghcA>?	NETsbnFFVVOR	MmrJTY5lfWOnczDhdI9xfG:\|aYO=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF3MkK0OUc,OjVzNUKyOFU9N2F-
MKN-45	M4HzfmFxd3Sxc3nzJGF{e2G7	MkHXNVAh\|ryP	NV\mXpNIPDhiaB?=	MorYSG1UVw>?	MVjJcoR2[2W\|IHHwc5B1d3Orcx?=	M1nlRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUWyNlQ2Lz5{NUG1NlI1PTxxYU6=
LNCaP	NYn0dIt[TnWwY4Tpc44hSXO\|YYm=	NE\xdo4yKM7:TR?=			MWLTeZBxemW\|c3XzJJAuSUuWIHzleoVtew>?	NXjVfY1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOlA4QTlpPkK1N\|YxPzl7PD;hQi=>
LNCaP95	NGL2OYJHfW6ldHnvckBCe3OjeR?=	MWKxJO69VQ>?			MWLTeZBxemW\|c3XzJJAuSUuWIHzleoVtew>?	MoizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NkC3PVkoRjJ3M{[wO\|k6RC:jPh?=
A549	NXzBOokyTnWwY4Tpc44hSXO\|YYm=	NV[5S29SPTByIH7N	Mo\jOFghcA>?	Mn[4SG1UVw>?	NILPU\|FKdmirYnn0d{BCc3RiYXP0bZZifGmxbh?=	M4XMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO3Nlk6Lz5{NUmzO\|I6QTxxYU6=
A549	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnrHNUDPxE1?	MonoO\|IhcA>?	NEXyUnZFVVOR	M4X4WmlvcGmkaYTzJINmdGxiZ4Lve5Rp	NVjNVoNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|czQTlpPkK1PVM4Ojl7PD;hQi=>
H522	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vOOFEh\|ryP	M2PVblczKGh?	NFfHNo1FVVOR	NXHuXHZZUW6qaXLpeJMh[2WubDDndo94fGh?	NEjkWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzO\|I6QSd-MkW5N\|czQTl:L3G+
SKMES-1	NHfTcFVEgXSxdH;4bYMhSXO\|YYm=	MnOzNUDPxE1?	MUW3NkBp		NEHoT4dKdmS3Y3XzJINmdGxiZHXheIg>	MkjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
H596	M1L1PWZ2dmO2aX;uJGF{e2G7	NF34R4EyKM7:TR?=			MXzJcZBicXK\|IHPlcIwhdWmpcnH0bY9v	NVXLNJFiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVM{OThpPkK2NFE{OzF6PD;hQi=>
HCC2450	NXzydHZKTnWwY4Tpc44hSXO\|YYm=	NHvYRXYyKM7:TR?=			MX\JcZBicXK\|IHPlcIwhcW64YYPpc44>	Mme3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUOzNVgoRjJ4MEGzN\|E5RC:jPh?=
HCT116	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHzpWoU4OiCqcoO=		MnS4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuOFgh\|ryPLh?=	Mn;mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
MCF7	M1\qbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NI\YV4o4OiCqcoO=		NVP1fZY5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxJO69VS5?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4NUmwPUc,OjV5NkW5NFk9N2F-
U87MG	MULBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Ml\oO\|IhcHK\|		MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFV6N13HJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLk[0JO69VS5?	Ml\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
A549	M3HvO2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NITOXFA4OiCqcoO=		M1;i[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj6wO{DPxE1w	M17ZOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
HeLa	NHfuTFRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWfOPZNSPzJiaILz		M2TBU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND6zOEDPxE1w	MoL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkW5NFkoRjJ3N{[1PVA6RC:jPh?=
HCT116	NXj4RYc5TnWwY4Tpc44h[XO\|YYm=	MVKxNEB2VQ>?	MoLzNUBpeg>?		MlPGTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhSWu2IIDoc5NxcG:{eXzheIlwdiCjdDCxNEB2VSCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfHSrbnegZY5idHm\|aYO=	M{fPfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{[1PVA6Lz5{NUe2OVkxQTxxYU6=
A2058 melanoma	M3eycWNmdGxiY4njcIUh[XO\|YYm=	M3e4NVUhfU1?	NUPvOlZ[OjRiaILz		M1XjemNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJGEzODV6IH3lcIFvd22jIHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCVdXLHNUBxcGG\|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	NX;aeHNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
A2058 melanoma	MnPpR4VtdCCleXPs[UBie3OjeR?=	M1H4ZlUhfU1?	M3r0PFI1KGi{cx?=		NHjsR4FE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjB3ODDt[Yxidm:vYTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJGZCS1NiYX7hcJl{cXN?	NXXrVYRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4Nlk2QTJpPkK4PFI6PTl{PD;hQi=>
SKOV3	MVvD[YxtKGO7Y3zlJIF{e2G7	M2PYTFIhfU1?	NF\kVFgzPCCqcoO=		NXzZZWZTS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhOiC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBHSUOVIHHuZYx6e2m\|	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mkm1PVIoRjJ6OEK5OVkzRC:jPh?=
SKOV3	NUXLXHNLS2WubDDjfYNt\SCjc4PhfS=>	MVqyJJVO	M3zkSVI1KGi{cx?=		NVzZTFlrS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hW0uRVkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGP1ZmcyKHCqYYPlJIF1KDJidV2gZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQhTkGFUzDhcoFtgXOrcx?=	M4XPPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK5OVkzLz5{OEiyPVU6OjxxYU6=
MDA-MB-231	NWn2S49YS3m2b4TvfIlkcXS7IHHzd4F6		MoHoO\|IhcHK\|		NVLLSFBPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU45QCEQvF2u	Mnv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEe0NlkoRjJ7MUC3OFI6RC:jPh?=
PC3	MkeyR5l1d3SxeHnjbZR6KGG\|c3H5		MYi3NkBpenN?		MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuN\|Qh\|ryPLh?=	NIHVc3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwO\|QzQSd-MkmxNFc1Ojl:L3G+
T47D	M3LjbmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnmzO\|IhcHK\|		NHjhXo5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA3Njl{IN88UU4>	M3[3VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
MCF7	MYDDfZRwfG:6aXPpeJkh[XO\|YYm=		NWq2NG44PzJiaILz		M2PIO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFEyNjB3IN88UU4>	M2X0R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUC3OFI6Lz5{OUGwO\|QzQTxxYU6=
TC32	MXHxTHRUKGG\|c3H5				NED2U5FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M2WyU5FJXFNiYYPzZZk>				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MmTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	M3TYRpFJXFNiYYPzZZk>				NEW1NnByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M{jVfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NFXqfVVyUFSVIHHzd4F6				Mnv0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	M3\vNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NGTRcItyUFSVIHHzd4F6				MmjOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	NETDXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NX3Vcm91eUiWUzDhd5NigQ>?				NHrmXnVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NEXDS3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M3f3[5FJXFNiYYPzZZk>				M3;sfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	M33qT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MWTxTHRUKGG\|c3H5				MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NWHZcHduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	Mm\WdWhVWyCjc4PhfS=>				M3TWfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	M3\2R5FJXFNiYYPzZZk>				M1vGRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	M4naXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	M3jrWpFJXFNiYYPzZZk>				MlHDdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NHTa[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	NHPFSZJyUFSVIHHzd4F6				NUXTRVdGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NH;VSW1yUFSVIHHzd4F6				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NHjsTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NF24N3JyUFSVIHHzd4F6				MknrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	M1nXZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NFPHWmlyUFSVIHHzd4F6				NYXIXYx5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIO=	M{DiXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NVvBdZV3eUiWUzDhd5NigQ>?				Ml\mdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	NWTYb3h3eUiWUzDhd5NigQ>?				NVexfplYeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	MlP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	Mnz4dWhVWyCjc4PhfS=>				M3\aNZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	MYnxTHRUKGG\|c3H5				NHrvZZFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NY\OTWhreUiWUzDhd5NigQ>?				NFS4OVNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	NYLzN\|RyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	M{DHWZFJXFNiYYPzZZk>				Ml7BdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M2HUSZFJXFNiYYPzZZk>				NGXEd5FyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NXi2bIxkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	M4rXc5FJXFNiYYPzZZk>				NYraV5NVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM>	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	MYrxTHRUKGG\|c3H5				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NUCyOYpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MWXxTHRUKGG\|c3H5				Mo\mdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	M3LMVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MoLwdWhVWyCjc4PhfS=>				MoHmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	NELMPHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	MVTxTHRUKGG\|c3H5				NFfjV4ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NFfqNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
insect	MkDQSpVv[3Srb36gZZN{[Xl?				M{jlUmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSHnzMZRi\2enZDDwPFVidHCqYT;wNVEx[WyyaHGgSVU1PUtibYX0ZY51KGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjBzMTFOwG0v	MkjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
insect	NWHHb\|VwTnWwY4Tpc44h[XO\|YYm=				MWfJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEircz30ZYdo\WRicEi1ZYxxcGFxcEGxNIFteGijIFW1OFJMKG23dHHueEBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE4xOjlizszNMi=>	NWS1WJRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
Sf21	M1HZd2Z2dmO2aX;uJIF{e2G7		NV7QZ5ZmOSCqch?=		NIG1dmRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwudGWwZ4ToJG4ufGW{bXnuZYwhUGm\|Nj30ZYdo\WRicEGxNIRmdHSjL4LlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJJA5PWGucHjhJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGmwc3XjeEBk\WyuczD1d4lv\yCSSWCyJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkAyKGi{IHL5JGFt\XijNkOzJHRz[WOncj3iZZNm\CCobIXvdoV{[2WwY3WgdI9t[XJuIFnDOVAhRSByLkGyOUDPxE1w	MlPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
MCF7	M2H4cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1jpRlczKGi{cx?=		M{DZ[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDoZZJjd3KrbnegVGlMO0ODIFW1OFVMKG23dHHueEBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4zODZizszNMi=>	M2nMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEO0OlA4Lz5\|MECzOFYxPzxxYU6=
Sf21	M4[5OGZ2dmO2aX;uJIF{e2G7		M33jfFEhcHJ?		MmLUTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsMYxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlKHBzMUDi[ZRiN3KnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIIC4OYFteGijIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkKxJIlve2WldDDj[YxteyC3c3nu[{BRUVB{IHHzJJN2[nO2cnH0[UBu\WG\|dYLl[EBi\nSncjCxJIhzKGK7IFHs[ZhiPjN\|IGTyZYNmei2kYYPl[EBndHWxcnXzZ4Vv[2VicH;sZZJqNCCLQ{WwJF0hOC5{M{Sg{txONg>?	NV3SXoJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
T47D	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4P0b\|czKGi{cx?=		M4fs[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVES3SEBk\WyuczDoZZJjd3KrbnegVGk{U0ODIFixNFQ4WiCvdYThcpQh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjh4IN88UU4>	MmfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{S2NFcoRjNyMEO0OlA4RC:jPh?=
PC3	NXThflk1TnWwY4Tpc44h[XO\|YYm=		NULNcXN1OiCqcoO=		MVfJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOnckS3N{Bu\WG\|dYLl[EBi\nSncjCyJIhzeyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTBiPTCwMlM3PSEQvF2u	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB\|NE[wO{c,OzByM{S2NFc9N2F-
HT-29	MoTER4VtdCCleXPs[UBie3OjeR?=	NIjNSZAxNjFzMTD0c{A{KHWP	NEjhOG8zPCCqcoO=		NWe5do5CS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFeyM20heGijc3WgZZQhOC5zMUGgeI8hOyC3TTDh[pRmeiB{NDDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?=	NV[5UGxERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|Q3ODdpPkOwNFM1PjB5PD;hQi=>
A2058	MVPGeY5kfGmxbjDhd5NigQ>?		NXrWNng6OSCqch?=		MmGyTY5pcWKrdHnvckBw\iCWT2LDNkBqdiCqdX3hckBCOjB3ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDheEBU\XJ2N{OgZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlQyPiEQvF2u	MnK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NUmwNFMoRjNyM{W5NFA{RC:jPh?=
A2058	MVPGeY5kfGmxbjDhd5NigQ>?		Mni0NUBpeg>?		M4rBV2lvcGmkaYTpc44hd2ZiVF;SR\|EhcW5iaIXtZY4hSTJyNUigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hWzZicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlI{PS9{M{[gZYZ1\XJiMTDodkBjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYOsJGlEPTBiPTCwMlU2OyEQvF2u	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN3OUCwN{c,OzB\|NUmwNFM9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT (T308) / p-AKT (S473) / AKT; PubMed: 27283525 J Neurooncol Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation. p-FOXO3a (S253) / FOXO3a; PubMed: 28036259 Oncotarget Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control. Nuclear NF-κB p65 / NF-κB p65; PubMed: 26673665 Cell Death Dis Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. p-ERK / ERK / LC3; PubMed: 27572309 Oncotarget The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins. p-STAT3 / STAT3 / p-ERK / ERK / p-S6; PubMed: 29928341 Oncol Lett Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h. p-MET / MET; PubMed: 29928341 Oncol Lett The expression of phosphorylated or total forms of MET protein was analyzed by western blotting.	27283525 28036259 26673665 27572309 29928341
Immunofluorescence	FOXO3a; PubMed: 28036259 Oncotarget Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.	28036259
Growth inhibition assay	Cell viability; PubMed: 26673665 Cell Death Dis Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).	26673665

体内研究

BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤，完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型，显示抗癌活性。^[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型，导致肿瘤体积和K链水平明显降低。^[2]

激酶实验：^[2]	- 合并 PI3K 生化实验(ATP 消耗实验): BKM120溶于DMSO中，按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl₂, 20 mM NaCl, 1 mM DTT，及0.05% CHAPS)，然后加到每孔中，随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗，然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟，然后通过荧光测定残留的ATP。
细胞实验：^[1]	- 合并 Cell lines: A2780细胞 Concentrations: 0-6.6 μM Incubation Time: 3天 Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔10³个细胞的密度接种在相同培养基上，温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中，在37^oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠 Dosages: ~60 mg/kg Administration: 每天口服处理 (Only for Reference)

参考文献

[4] Koul D, et al. Clin Cancer Res, 2012, 18(1), 184-195.

- 合并

溶解度 (25°C)

体外	DMSO	82 mg/mL (199.8 mM)
	Ethanol	2 mg/mL (4.87 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+30% PEG 300+ddH2O	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Buparlisib (BKM120) SDF

分子量	410.39
化学式	C₁₈H₂₁F₃N₆O₂
CAS号	944396-07-0
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04338399	Recruiting	Drug: Buparlisib & Paclitaxel	Head and Neck Cancer	Adlai Nortye Biopharma Co. Ltd.	December 12 2020	Phase 3
NCT02614508	Terminated	Drug: Buparlisib\|Drug: Ibrutinib\|Biological: Ofatumumab	Recurrent Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Small Lymphocytic Lymphoma	Emory University\|Novartis	January 2016	Phase 1
NCT02194049	Completed	Drug: BKM120\|Drug: cisplatin\|Drug: etoposide	Extensive Stage Small Cell Lung Cancer\|Unspecified Adult Solid Tumor Protocol Specific	University of California Davis\|Novartis	July 2014	Phase 1
NCT02154776	Completed	Drug: LEE011\|Drug: Buparlisib\|Drug: Letrozole	Advanced or Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	June 27 2014	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

选择性强的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
选择性强的PI3K抑制剂

TGX-221 : p110β-specific, IC50=5 nM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

定制您的化合物库

Buparlisib (BKM120)

客户使用Selleck生产的Buparlisib (BKM120)发表文献208篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Buparlisib (BKM120) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品